Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy

Journal of Rheumatology

Volumn 42, Issue 3, 2015, Pages 372-378

  Aaltonen, Kalle Jyri ^a   Joensuu, Jaana Tuulikki ^a   Virkki, Liisa ^a   Sokka, Tuulikki ^c   Aronen, Pasi ^a   Relas, Heikki ^b   Valleala, Heikki ^b   Rantalaiho, Vappu ^d   Pirilä, Laura ^e   Puolakka, Kari ^f   Uusitalo, Tea ^g   Blom, Marja ^a   Konttinen, Yrjö Tapio ^a,b   Nordström, Dan ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^g KANTA HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

Antibodies; Epidemiology; Infection; Monoclonal; Neoplasms; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; FINLAND; INCIDENCE; MIDDLE AGED; NEOPLASMS; REGISTER;

ADALIMUMAB; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; FINLAND; HUMANS; INCIDENCE; INFECTION; INFLIXIMAB; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RITUXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923914090     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140853     Document Type: Article

References (26)

1. Finnish Medical Society Duodecim and the Finnish Society for Rheumatology. [Rheumatoid arthritis. Current care guideline]. [Article in Finnish] [Internet. Accessed November 25, 2014.] Available from: www.kaypahoito.fi/web/english/guidelines/guideline?id=ccs00063&suositusid=hoi21010
2. Aaltonen K, Sokka T, Möttönen T, Korpela M, Komulainen R, Uusitalo T, et al. A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland. Scand J Rheumatol 2014;43:286-90.
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
4. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
5. Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939.
6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
7. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
8. Konttinen L, Honkanen V, Uotila T, Pöllänen J, Waahtera M, Romu M, et al. Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 2006;26:916-22.
9. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275.
10. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
11. van Dartel SS, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895-900.
12. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
13. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35.
14. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011;31:1493-9.
15. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
16. Finnish Cancer Registry. Institute for Statistical and Epidemiological Cancer Research. [Internet. Accessed November 25, 2014.] Available from: www.cancer.fi/syoparekisteri/en/
17. National Institute for Health and Welfare. Specialized health care services. [Internet. Accessed November 25, 2014.] Available from: www.thl.fi/en/web/thlfi-en/statistics/statistics-by-topic/specialised-health-care-services
18. Faraway JJ. Extending the linear model with r: generalized linear, mixed effects and nonparametric regression models. Boca Raton: Chapman and Hall/CRC Press; 2005.
19. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
20. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794.
21. Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011;38:1552-62.
22. Virkki L, Aaltonen K, Nordström DC. [Biological therapy in rheumatoid arthritis based on ten years of registry surveillance in Finland]. [Article in Finnish] Duodecim 2010;126:1487-95.
23. Sokka T. Rheumatoid arthritis databases in Finland. Clin Exp Rheumatol 2005;23:S201-4.
24. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
25. Aaltonen KJ, Virkki LM, Jämsen E, Sokka T, Konttinen YT, Peltomaa R, et al. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. Semin Arthritis Rheum 2013;43:55-62.
26. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93.